Neonatal outcomes
| Study infants | Historical controls | Study infants | Historical controls | |
|---|---|---|---|---|
| 25–28 weeks, n=11 | 25–28 weeks, n=29 | 29–34 weeks, n=14 | 29–34 weeks, n=144 | |
| Intubated in first 72 h of life | 3 (27%) | 17 (59%) | 0 (0%) | 22 (15%) |
| Surfactant given after intubation | 1 (9%) | 16 (55%) | 0 (0%) | 23 (16%) |
| Intubated at any time | 6 (55%) | 20 (69%) | 0 (0%) | 26 (18%) |
| Pneumothorax | 1 (9%) | 6 (21%) | 0 (0%) | 11 (7.6%) |
| PDA treated with indomethacin | 5 (45%) | 11 (38%) | 1 (7%) | 7 (4.9%) |
| Chronic lung disease in survivors | 3/10 (30%) | 4/26 (15%) | 0 (0%) | 1/142 (0.7%) |
| IVH (any) | 2 (18%) | 7 (24%) | 1 (7%) | 11 (7.6%) |
| IVH III or IV | 0 (0%) | 3 (10%) | 0 (0%) | 4 (2.8%) |
| ROP > stage 2 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.7%) |
| Died | 1 (9%) | 3 (10%) | 0 (0%) | 2 (1.4%) |
n (%). Historical controls from the years 2006–2008, including only inborns for 25–28-week gestation group. See text for details of statistical comparisons between study infants and controls.
IVH, intraventricular haemorrhage; PDA, patent ductus arteriosus; ROP, retinopathy of prematurity.